skip to main content

Anti-Ro/SSA-associated cardiac neonatal lupus — SCE Rheumatology MCQ

Instant feedback + full explanation. One question, done properly.

ModeratePregnancy in Rheumatic Disease and Rare ConditionsAnti-Ro/SSA-associated cardiac neonatal lupusSCE Rheumatology

A 31-year-old woman with anti-Ro/SSA-positive Sjögren disease is reviewed at 7 weeks’ gestation. Her disease is clinically quiescent, and she stopped hydroxychloroquine 6 months ago because she wished to reduce medication use. Her previous child developed congenital complete heart block and required permanent pacing. The current pregnancy is viable, and she has no contraindication to hydroxychloroquine. In addition to specialist fetal surveillance, which pharmacological strategy is most appropriate to reduce the risk of recurrent cardiac neonatal lupus?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: E — Start hydroxychloroquine 400 mg daily now and continue throughout pregnancy

The previous anti-Ro/SSA-associated congenital heart block identifies a high-recurrence-risk pregnancy; maternal rheumatic disease activity need not be present for cardiac neonatal lupus to occur. Hydroxychloroquine should be restarted promptly. In the prospective PATCH study, anti-Ro-positive women with a previously affected pregnancy received hydroxychloroquine 400 mg daily before completion of gestational week 10 and continued it throughout pregnancy. Advanced congenital heart block occurred in 7.4%, compared with the historical recurrence rate of approximately 18%. UK BSR guidance supports hydroxychloroquine use during pregnancy at doses up to 400 mg/day. Prednisolone may be used for maternal inflammatory disease but is not an evidence-based substitute for hydroxychloroquine as secondary fetal prophylaxis. Low-dose intravenous immunoglobulin has been prospectively studied in this setting without preventing recurrence. Prophylactic dexamethasone exposes mother and fetus to a fluorinated glucocorticoid without established preventive benefit; its possible role is confined to selected fetuses with evolving cardiac disease and remains controversial. Surveillance remains necessary because hydroxychloroquine does not abolish risk, but waiting for conduction abnormalities misses the evidence-based early prophylactic window and established complete block is generally irreversible.

Reference: BSR stands by pregnancy guideline recommendations on the safety of HCQ (12 June 2023) — https://www.rheumatology.org.uk/news/details/BSR-stands-by-pregnancy-guideline-recommendations-on-the-safety-of-HCQ-?articleId=781 Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers (2020) — https://pubmed.ncbi.nlm.nih.gov/32674792/ Treatment options for preventing autoimmune-mediated congenital heart block: a systematic review (2025) — https://pubmed.ncbi.nlm.nih.gov/39890428/